Results 121 to 130 of about 11,033 (240)

Population pharmacokinetics and pharmacodynamics of nasal glucagon in patients with type 1 or 2 diabetes

CPT: Pharmacometrics & Systems Pharmacology
The objective was to characterize the pharmacokinetics (PK) and pharmacodynamics (PD) of glucagon after injectable or nasal administration and confirm the appropriate therapeutic dose of nasal glucagon (NG) for adult patients.
Douglas E. James, Tong Shen, Jeanne S. Geiser, Parag Garhyan, Emmanuel Chigutsa   +4 more
doaj   +1 more source

Clinical Pharmacology Quality Assurance Program for Global HIV and Co‐Infection Drug Development

Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1205-1215, May 2026.
When the acquired immunodeficiency syndrome emerged in the 1980s, the United States National Institutes of Health established research networks to conduct clinical trials with the pharmaceutical industry to identify effective antiretroviral therapeutics.
Robin DiFrancesco, Troy D. Wood, Raymond Cha, Jill S. Hochreiter, Susan L. Rosenkranz, Mona Farhad, Kyle R. Whitson, Connor E. Gould, Lauren E. Hill, Linda L. Hale, Philip H. Lindhorst, Diala Ghazal, Charlene R. Taylor, Madiha Quraishi, Suzanne M. Siminski, Yoninah Cramer, Heather L. Sprenger, Gene D. Morse   +17 more
wiley   +1 more source

Development of a Novel Machine Learning Method for Estimation of Life‐Long Chronic Disease Progression and Its Application to Type 2 Diabetes

Clinical and Translational Science
Individual predictions of long‐term chronic disease progression from data of limited duration provide valuable insights into estimating patient outcomes and therapeutic needs.
Yamato Sano, Ryota Jin, Hideki Yoshioka, Yuki Nakazato, Hiromi Sato, Akihiro Hisaka   +5 more
doaj   +1 more source

Machine Learning Meets Pharmacokinetics: A Comparative Analysis of Predictive Models for Plasma Concentration‐Time Profiles

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 5, May 2026.
ABSTRACT Predicting pharmacokinetic (PK) profiles from molecular structures represents a significant advancement in pharmaceutical research with substantial implications for expediting drug discovery processes. We evaluated five approaches to systematically compare five distinct methodological frameworks for predicting rat plasma concentration‐time ...
Felix Jost, Clemens Giegerich, Christoph Grebner, Hans Matter, Henrik Cordes   +4 more
wiley   +1 more source

Integration of Time‐Varying Pharmacometric Modeling With Cox Regression for Time‐to‐Event Analysis in NONMEM

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 5, May 2026.
ABSTRACT Although time‐varying Cox regression modeling approaches have been developed, exposure–response analyses for time‐to‐event (TTE) endpoints often rely on static exposure covariates and may overlook the real‐world dosing variability and drug concentration fluctuations over time. To better characterize pharmacokinetic (PK) or pharmacodynamic (PD)
Chih‐Wei Lin, Po‐Wei Chen, Sameer Doshi, Sandeep Dutta   +3 more
wiley   +1 more source

Optimizing Vancomycin Dosing in Chronic Kidney Disease by Deriving and Implementing a Web-Based Tool Using a Population Pharmacokinetics Analysis. [PDF]

, 2019
Background: Chronic kidney disease (CKD) patients requiring intravenous vancomycin bear considerable risks of adverse outcomes both from the infection and vancomycin therapy itself, necessitating especially precise dosing to avoid sub- and ...
Chae, Jung-Woo, Chan, Alexandre, Dorajoo, Sreemanee Raaj, Goh, Jessica Hui Fen, Lee, Siok Ying, Ooi, Say Tat, Somani, Jyoti, Winata, Chrystal Leandra, Yap, Chun Wei, Yeoh, Lee Ying   +9 more
core  

Autosomal Dominant Tubulointerstitial Kidney Disease Clinical Trial Simulator: Case Reports of Model‐Informed Drug Development

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 5, May 2026.
ABSTRACT Autosomal Dominant Tubulointerstitial Kidney Disease (ADTKD) is the third most common inherited monogenic kidney disorder. Mutations in UMOD and MUC1 account for most cases, with the disease characterized by progressive eGFR decline leading to kidney failure. No disease‐modifying therapies exist, and transplantation is the only current option.
Shyam S. Ramesh, Mark Rogge, Jongjin Kim, Sanghoon Kang, Kendrah Kidd, Adrienne Williams, Julie Roignot, Katherine Blakeslee, Anthony J. Bleyer, Sarah Kim   +9 more
wiley   +1 more source

Model-based meta-analysis of HbA1c reduction across SGLT2 inhibitors using dose adjusted by urinary glucose excretion

Scientific Reports
This study was aimed to evaluate whether the dose–response relationship of the sodium glucose co-transporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM)—canagliflozin, dapagliflozin, empagliflozin, ipragliflozin ...
Hiromi Sato, Ayana Ishikawa, Hideki Yoshioka, Ryota Jin, Yamato Sano, Akihiro Hisaka   +5 more
doaj   +1 more source

Opportunities and Challenges of Using Big Data to Detect Drug-Drug Interaction Risk [PDF]

, 2019
Chasioti D., Institute of Medicine Committee on Data Standards for Patient Safety   +1 more
core   +1 more source

An Interactive Pharmacokinetic‐Pharmacodynamic Framework to Evaluate Bedaquiline Dose Modifications in Adults With Tuberculosis

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 5, May 2026.
ABSTRACT Bedaquiline is approved for use in a thrice‐weekly dosing schedule; simpler once‐daily dosing strategies could enable fixed‐dose combinations and improve patient adherence. We developed an interactive R Shiny simulation tool to enable the evaluation of different bedaquiline dosing schedules within an integrated dose‐pharmacokinetic‐efficacy ...
Yu‐Jou Lin, Frances Okibedi, Mats O. Karlsson, Elin M. Svensson   +3 more
wiley   +1 more source